tbuckley/cabot-search huggingface dataset:
TMIC-19. KNOCKDOWN OF TUMOR-DERIVED OSTEOPONTIN/SPP1 OR APPLICATION OF A BLOCKING PEPTIDE RESTORES ANTI-TUMOR RESPONSES IN EXPERIMENTAL RAT GLIOMAS
Authors: Bozena Kaminska, Anna Gieryng
Journal: Neuro-Oncology (2016)

Malignant glioma produced factors that attract and re-program microglia and infiltrating peripheral macrophages into proinvasive, immunosuppressive cells. This creates immunosuppressive milieu and inhibits responses of infiltrating T cells. Recently, we identified glioma-processed osteopontin/Spp1 as a major microglia-activating factor. Spp1 is a small glycoprotein, interacting via a RGD motif with integrin receptors on immune cells and via a CD44 binding domain with a CD44 on tumor cells. Tumor-processed Spp1 induces the pro-invasive re-programming of microglia in vitro. Knockdown of Spp1 in C6 glioma inhibits growth of intracranial gliomas and reduces the number of microglia/macrophages expressing Arg1 and CD163, markers of a protumorigenic phenotype. Moreover, T lymphocytes infiltrating Spp1-depleted gliomas show signs of restoration of antitumor activity and exhibit upregulated expression of cytotoxic mediators. To investigate if protumorigenic effects of Spp1 depends on its support for glioma cells self-renewal or interactions with microenvironment, we re-expressed constructs coding for the wild type Spp1, CD44 binding domain lacking or the RGD mutated Spp1, in glioma cells lacking endogenous Spp1 and performed whole brain imaging to measure resulting tumors. Re-expression of the RGD mutated Spp1 did not restore tumor growth in vivo suggesting that interactions with integrin receptors on microglia is vital for tumor growth. We designed and tested a 7-aa peptide interfering with integrin ligand binding; the peptide blocked efficiently migration, phagocytosis and glioma-induced integrin signaling in cultured microglia exposed to glioma. C6 glioma cells co-implanted with the peptide formed smaller tumors than those co-implanted with a scrambled peptide. Our results show that tumor-derived SPP1 via its RGD motif activates infiltrating microglia/macrophages, reprograms these cells into proinvasive and immunosuppressive cells that create a specific microenvironment, which contributes to glioma progression. Targeting glioma-microglia interactions with short interfering peptides could be a novel therapeutic strategy. Studies were supported by a grant 2012/04/A/NZ3/00630 from the National Science Center.
Effects of salmeterol fluticasone plus tiotropium bromide on right cardiac and thyroid functions of patients of chronic obstructive pulmonary disease with chronic cor pulmonale
Authors: Dai Li, Hong Teng, Hong Qiu
Journal: BMJ (2014)

Objective
To explore the influence of salmeterol fluticasone plus tiotropium bromide on right cardiac and thyroid functions of patients of chronic obstructive pulmonary disease(COPD)with chronic cor pulmonale.


Methods
A total of 92 cases of COPD patients with chronic cor pulmonale at our hospital from July to December 2012 were recruited as subjects and divided randomly into 2 groups of treatment (n=47) and control (n=45). The control group received diuretics and vasodilative drugs while the treatment group had additional therapies of salmeterol fluticasone (50/500 μg) twice daily plus tiotropium bromide once per day once daily for 6 months. Measure and compare two groups of patients' FEV1%, forced expiratory volume in one second(FEV1), status of vigor, brain natriuretic peptide(BNP), left ventricular ejection fraction (LVEF), ultrasonic cardiogram (right ventricular outflow tract, right ventricular internal diameter, right pulmonary artery trunk) and value of thyroid function before and after treatment.


Results
Before treatment, the treatment group's FEV1(%)(36±10)%, FEV1(1 036±410)ml, BNP (357±101) ng/L, LVEF (46.2±10.4)%, internal diameter of right ventricular outflow tract (36.0±5.4) mm, right ventricular internal diameter (38.1±6.7) mm, right pulmonary artery trunk (24.0±3.6) mm, TT3 (1.47±0.38) nmol/L, TT4 (114.56±21.39) nmol/L, FT3 (4.47±1.42) pmol/L, FT4 (15.6±2.5) pmol/L and TSH (2.50±0.91) mU/L showed no marked difference from those of control group (P>0.05). After treatment, the treatment group's FEV1(%)(58±1)%, FEV1(1 706±456)ml, BNP(225±52) ng/L, LVEF (57.1±11.5)%, internal diameter of right ventricular outflow tract (30.1±4.2) mm, right ventricular internal diameter (32.0±3.9) mm and right pulmonary artery trunk (20.2±2.3) mm greatly improved (P 0.05). However, no obvious difference existed in the control group's BNP, LVEF, internal diameter of right ventricular outflow tract, right ventricular internal diameter, right pulmonary artery trunk and value of thyroid function before and after treatment (P>0.05).


Conclusion
Salmeterol fluticasone plus tiotropium bromide can effectively improve right cardiac functions of patients of COPD with chronic cor pulmonale, without marked suppression of thyroid function.


Key words: 
Drug threapy, combination; Pulmonary disease, chronic obstractive; Pulmonary heart disease
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
Authors: Julian Panés, William J Sandborn, Stefan Schreiber, Bruce E Sands, Séverine Vermeire, Geert D'Haens, Remo Panaccione, Peter D R Higgins, Jean-Frederic Colombel, Brian G Feagan, Gary Chan, Michele Moscariello, Wenjin Wang, Wojciech Niezychowski, Amy Marren, Paul Healey, Eric Maller
Journal: Gut (2017)

<h3>Objective</h3> Tofacitinib is an oral, small-molecule Janus kinase inhibitor that is being investigated for IBD. We evaluated the efficacy and safety of tofacitinib for induction and maintenance treatment in patients with moderate-to-severe Crohn9s disease (CD). <h3>Design</h3> We conducted two randomised, double-blind, placebo-controlled, multicentre phase IIb studies. Adult patients with moderate-to-severe CD were randomised to receive induction treatment with placebo, tofacitinib 5 or 10 mg twice daily for 8 weeks. Those achieving clinical response-100 or remission were re-randomised to maintenance treatment with placebo, tofacitinib 5 or 10 mg twice daily for 26 weeks. Primary endpoints were clinical remission at the end of the induction study, and clinical response-100 or remission at the end of the maintenance study. <h3>Results</h3> 180/280 patients randomised in the induction study were enrolled in the maintenance study. At week 8 of induction, the proportion of patients with clinical remission was 43.5% and 43.0% with 5 and 10 mg twice daily, respectively, compared with 36.7% in the placebo group (p=0.325 and 0.392 for 5 and 10 mg twice daily vs placebo). At week 26 of maintenance, the proportion of patients with clinical response-100 or remission was 55.8% with tofacitinib 10 mg twice daily compared with 39.5% with tofacitinib 5 mg twice daily and 38.1% with placebo (p=0.130 for 10 mg twice daily vs placebo). Compared with placebo, the change in C-reactive protein from baseline was statistically significant (p&lt;0.0001) with 10 mg twice daily after both induction and maintenance treatments. <h3>Conclusions</h3> Primary efficacy endpoints were not significantly different from placebo, although there was evidence of a minor treatment effect. No new safety signals were observed for tofacitinib. <h3>Trial registration numbers</h3> NCT01393626 and NCT01393899.
Sokal Risk Score Is Superior to Hasford and EUTOS in Determining Survival Outcomes for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
Authors: Brian Gabriel Jiang, Dong-Wook Kim, Lee-Yung Shih, Charles Chuah, Hein Than, Ming-Chung Kuo, HuiHua Li, John Carson Allen, Lionel KY See, Bernard KC Yap, Yeow-Tee Goh
Journal: Blood (2015)
High Expression of the Thalidomide-Binding Protein Cereblon (CRBN) Is Associated with Improved Clinical Response in Patients with Multiple Myeloma Treated with Lenalidomide and Dexamethasone
Authors: Daniel Heintel, Arnold Bolomsky, Martin Schreder, Sabine Pfeifer, Niklas Zojer, Ulrich Jäger, Heinz Ludwig
Journal: Blood (2011)
Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA study
Authors: Philippe Carron, Gaëlle Varkas, Heleen Cypers, Liesbet Van Praet, Dirk Elewaut, Filip Van den Bosch
Journal: Annals of the Rheumatic Diseases (2017)

To evaluate the efficacy and safety of golimumab to induce clinical remission in patients with very early, active peripheral spondyloarthritis (pSpA).Clinical REmission in peripheral SPondyloArthritis is a monocentric study of golimumab treatment in patients with pSpA. All patients fulfilled the Assessment of SpondyloArthritis international Society classification criteria for pSpA, with a symptom duration ≤12 weeks. Patients were randomised 2:1 to receive golimumab 50 mg every 4 weeks or matching placebo for 24 weeks. The primary end point was the percentage of patients achieving clinical remission at week 24, defined as absence of arthritis, enthesitis and dactylitis. Secondary end points included joint and enthesis counts, patient-reported outcomes, erythrocyte sedimentation rate and C reactive protein. From week 12, non-responders were allowed to receive rescue medication with golimumab. Adverse events were recorded.60 patients were randomised with similar baseline characteristics. At week 24, a significantly higher percentage of patients receiving golimumab achieved clinical remission compared with placebo (75% (30/40) vs 20% (4/20); p<0.001). At week 12, similar results were observed (70% (28/40) vs 15% (3/20); p<0.001). All secondary end points were met at week 24. Rescue medication was necessary in 50% in the placebo group opposed to only 10% in the golimumab arm. Rates of adverse events were low and similar in both groups.Markedly high remission induction rates were noted with golimumab in very early pSpA. Of interest, in placebo-treated patients, very low spontaneous remission rates were observed.NCT01426815; Results.
The MITCI (phase 1b) study: a novel immunotherapy combination of coxsackievirus A21 and ipilimumab in patients with advanced melanoma
Authors: B. Curti, J. Richards, M. Faries, R.H.I. Andtbacka, M. Grose, R. Karpathy, D. Shafren
Journal: Annals of Oncology (2016)
PSA-PFS in metastatic or high risk prostate cancer patients treated with GnRH antagonist (degarelix) versus LHRH agonists – A pooled analysis of data from the Americas, Europe and Asia
Authors: N. Shore, Z. Bosnyak, M. Gittelman, A. Malmberg, P.-A. Abrahamsson, L.-P. Xie
Journal: Annals of Oncology (2016)
Trends in carbapenemase-producing Enterobacteriaceae, France, 2012 to 2014
Authors: Laurent Dortet, Gaëlle Cuzon, Valérie Ponties, Patrice Nordmann
Journal: Eurosurveillance (2017)

In 2014, a total of 2,976 Enterobacteriaceae isolates with decreased susceptibility to carbapenems were received at the French Associated National Reference Center for Antibiotic Resistance (NRC) and were characterised for their molecular resistance mechanism to carbapenems and compared with results obtained during 2012 and 2013.The overall number of enterobacterial isolates with decreased susceptibility to carbapenems received at the NRC rapidly increased (more than twofold in two years) with a growing proportion of carbapenemase producers (23.1% in 2012 vs 28.6% in 2013 vs 36.2% in 2014). Between 2012 and 2014, the main carbapenemase type was OXA-48, with an increase in OXA-48 variants (mostly OXA-181) and NDM producers, whereas the number KPC producers decreased. We identified a potential spread of OXA-181 producers in the tropical region of Africa. Finally, OXA-48 and OXA-48-related enzymes remained the predominant carbapenemases in France. The number of carbapenemase-producing Escherischia coli isolates was multiplied by fivefold between 2012 and 2014, suggesting a possible dissemination in the community.
Ultra-rare genetic variation in common epilepsies: a case-control sequencing study
Authors: Andrew S Allen, Susannah T Bellows, Samuel F Berkovic, Joshua Bridgers, Rosemary Burgess, Gianpiero Cavalleri, Seo-Kyung Chung, Patrick Cossette, Norman Delanty, Dennis Dlugos, Michael P Epstein, Catharine Freyer, David B Goldstein, Erin L Heinzen, Michael S Hildebrand, Michael R Johnson, Ruben Kuzniecky, Daniel H Lowenstein, Anthony G Marson, Richard Mayeux, Caroline Mebane, Heather C Mefford, Terence J O'Brien, Ruth Ottman, Steven Petrou, Slavgé Petrovski, William O Pickrell, Annapurna Poduri, Rodney A Radtke, Mark I Rees, Brigid M Regan, Zhong Ren, Ingrid E Scheffer, Graeme J Sills, Rhys H Thomas, Quanli Wang, Bassel Abou-Khalil, Brian K Alldredge, Dina Amrom, Eva Andermann, Frederick Andermann, Jocelyn F. Bautista, Samuel F Berkovic, Judith Bluvstein, Alex Boro, Gregory D Cascino, Damian Consalvo, Patricia Crumrine, Orrin Devinsky, Dennis Dlugos, Michael P Epstein, Miguel Fiol, Nathan B Fountain, Jacqueline French, Catharine Freyer, Daniel Friedman, Eric B Geller, Tracy Glauser, Simon Glynn, Kevin Haas, Sheryl R Haut, Jean Hayward, Sandra L Helmers, Sucheta Joshi, Andres Kanner, Heidi E Kirsch, Robert C Knowlton, Eric H Kossoff, Rachel Kuperman, Ruben Kuzniecky, Daniel H Lowenstein, Paul V Motika, Edward J Novotny, Ruth Ottman, Juliann M Paolicchi, Jack M Parent, Kristen Park, Annapurna Poduri, Lynette G Sadleir, Ingrid E Scheffer, Renée A. Shellhaas, Elliott H Sherr, Jerry J. Shih, Shlomo Shinnar, Rani K Singh, Joseph Sirven, Michael C Smith, Joseph Sullivan, Liu Lin Thio, Anu Venkat, Eileen P.G Vining, Gretchen K Von Allmen, Judith L Weisenberg, Peter Widdess-Walsh, Melodie R Winawer
Journal: The Lancet Neurology (2017)
ATIM-07. TARGETING MYELOID DERIVED SUPPRESSOR CELLS: PHASE 0/1 TRIAL OF LOW DOSE CAPECITABINE + BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA
Authors: David Peereboom, Justin Lathia, Maksim Sinyuk, Cathy Brewer, Manmeet Ahluwalia, Michael Vogelbaum
Journal: Neuro-Oncology (2016)
Extracellular Matrix Receptor Expression in Subtypes of Lung Adenocarcinoma Potentiates Outgrowth of Micrometastases
Authors: Laura E. Stevens, William K.C. Cheung, Sally J. Adua, Anna Arnal-Estapé, Minghui Zhao, Zongzhi Liu, Kelly Brewer, Roy S. Herbst, Don X. Nguyen
Journal: Cancer Research (2017)

Abstract Mechanisms underlying the propensity of latent lung adenocarcinoma (LUAD) to relapse are poorly understood. In this study, we show how differential expression of a network of extracellular matrix (ECM) molecules and their interacting proteins contributes to risk of relapse in distinct LUAD subtypes. Overexpression of the hyaluronan receptor HMMR in primary LUAD was associated with an inflammatory molecular signature and poor prognosis. Attenuating HMMR in LUAD cells diminished their ability to initiate lung tumors and distant metastases. HMMR upregulation was not required for dissemination in vivo, but enhanced ECM-mediated signaling, LUAD cell survival, and micrometastasis expansion in hyaluronan-rich microenvironments in the lung and brain metastatic niches. Our findings reveal an important mechanism by which disseminated cancer cells can coopt the inflammatory ECM to persist, leading to brain metastatic outgrowths. Cancer Res; 77(8); 1905–17. ©2017 AACR.
Biological Rational for the Use of Heparin in Septic Shock: Translational Data from the Halo Pilot RCT
Authors: Brett L. Houston, Dhruva J. Dwivedi, Peter Grin, Michelle Kwong, Enrico Rullo, Momina A. Khan, Senay Asma, Guillaume Pare, Patricia C. Liaw, Ryan Zarychanski, Alison E. Fox-Robichaud
Journal: Blood (2015)
Refined Cytogenetic Risk Categorization for Overall and Leukemia-Free Survival In Primary Myelofibrosis: A Single Center Study of 433 Patients
Authors: Domenica Caramazza, Kebede Begna, Naseema Gangat, Rakhee Vaidya, Sergio Siragusa, Daniel L. Van Dyke, Curtis A. Hanson, Animesh Pardanani, Ayalew Tefferi
Journal: Blood (2010)
Efficient Transduction of Common Marmoset (Callithrix jacchus) Hematopoietic and Embryonic Stem Cells Using Foamyvirus Vectors.
Authors: Peter A. Horn, Melanie Wurm, Ryo Kurita, Tomoko Yokoo, Rainer Blasczyk, Dirk Lindemann, Helmut Hanenberg, Kenzaburo Tani
Journal: Blood (2005)
Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial
Authors: Pierre Asfar, Frédérique Schortgen, Julie Boisramé-Helms, Julien Charpentier, Emmanuel Guérot, Bruno Megarbane, David Grimaldi, Fabien Grelon, Nadia Anguel, Sigismond Lasocki, Matthieu Henry-Lagarrigue, Frédéric Gonzalez, François Legay, Christophe Guitton, Maleka Schenck, Jean Marc Doise, Jérôme Devaquet, Thierry Van Der Linden, Delphine Chatellier, Jean Philippe Rigaud, Jean Dellamonica, Fabienne Tamion, Ferhat Meziani, Alain Mercat, Didier Dreyfuss, Valérie Seegers, Peter Radermacher
Journal: The Lancet Respiratory Medicine (2017)
Acknowledging and Overcoming Nonreproducibility in Basic and Preclinical Research
Authors: John P. A. Ioannidis
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ERA-Net TRANSCAN JTC 2011: Critical aspects of the startup procedures of an International Academic Clinical trial (ET-FES), funded by the European Community (EC) and coordinated by an Italian Institution.
Authors: M. Monti, D. Corradengo, O. Nanni, A. Piccardo, F. Matteucci, E. Brain, J. Cortes, N. Harbeck, R. Wuerstlein, A. Piris, D.F. Merlo, T. Degenhardt, A. Cesario, E. Rivitti, G.A. Rollandi, M. Iacozzi, E. Campazzi, S. Campora, D. Camporese, A. Gennari
Journal: Annals of Oncology (2016)
RTHP-30. ENHANCED THERAPEUTIC BENEFITS OF TUMOR TREATING FIELDS (TTFIELDs) ON SUPERFICIALLY LOCATED GLIOBLASTOMA MULTIFORME (GBM)
Authors: David Harris, Vaibhav Kumar
Journal: Neuro-Oncology (2016)

and delivery time (evaluation with Mobius3d) were charted for each plan.Detailed results will be presented at the meeting.VMAT plans with varying dose prescriptions for multiple BM, had comparable dosimetric coverage as static beam plans for regular and more complex shapes, but were obtained with faster delivery time.For irregular and very long/narrow target shapes, VMAT optimization process might be of advantage, probably due to the optimization process during inverse planning.The use of static beams is more demanding, nevertheless can yield comparable efficient dose distribution, though with lower overall monitor units.
Thrombosis in MPN with Thrombocythemia Is Associated with Higher Platelet Count At the Time of the Event: Data From the Czech Registry of Patients Treated with Anagrelide,
Authors: Jiri Schwarz, Miroslav Penka, Petra Ovesna, Olga Cerna, Yvona Brychtova, Petr Dulicek
Journal: Blood (2011)
Outcomes of primary plasmacytoma (PP) in United States (US).
Authors: Guru Subramanian Guru Murthy, Raji Venkitachalam, Vijaya Raj Bhatt, Ishwori Dhakal, Jeanette Y. Lee, Yogesh Jethava, Peter D. Emanuel, Paulette Mehta
Journal: Journal of Clinical Oncology (2015)

8597 Background: Studies on multiple myeloma demonstrate an improvement in overall survival (OS) and increased risk of second primary malignancy (SPM); Population level data on OS and the risk of SPM in primary plasmacytoma (PP) is sparse. Hence, we aimed to determine the trends in OS and SPM in patients with PP in US. Methods: The Surveillance, Epidemiology and End Results (SEER-13) database was used to identify patients with age > 20, diagnosed with solitary plasmacytoma of bone (SPB) or extramedullary plasmacytoma (EMP) (ICD-O-3 codes –9731, 9734) as the first primary malignancy between 1992 to 2011. OS analysis was performed using Kaplan-Meier method and compared by log rank test. SPM was identified using SEERstat software (version 8.1.5) with a latency period of 6 months from radiotherapy (RT). Multivariate analysis of OS was performed using Cox proportional hazard regression method. Results: 2064 patients with SPB/EMP had a median age of 62 years (range 20-96). Baseline characteristics included 63.6% males, 54.2% with age > 60, 79.2% Whites, 14% African americans and 6.8% other races. About 48.4% of patients received RT alone, 23.5% had surgery and RT, 10.5% had surgery and 17.6% did not receive surgery or RT. OS at 10 years was higher in patients with age < 60 vs. age > 60 (62.5% vs. 22.2%, p < 0.01) and for other races vs. Whites vs. African americans (51.1% vs. 40.1% vs. 34.5% respectively, p = 0.01). Use of RT and surgery resulted in better 10-year OS (51.2%) than surgery alone (44.1%), RT alone (39.8%) or no RT/surgery (21.2%) (p < 0.01).On multivariate analysis, age > 60 (HR 3.01, 95% CI 2.61-3.46; p < 0.01), Whites vs. other races (HR 1.35, 95% CI 1.02-1.77; p = 0.03) and African americans vs. other races (HR 1.52, 95% CI 1.11-2.08; p < 0.01) predicted worse OS, whereas the use of RT along with surgery Vs. RT alone (HR 0.82, 95% CI 0.70-0.97; p = 0.02) predicted better OS. Patients treated with RT had more SPM as compared to general population- all sites standardized incidence ratio (SIR) 1.49, with more leukemia/lymphoma (SIR 6.37) and bone tumors (SIR 19.93) (p < 0.05). Conclusions: Our study demonstrates that the use of RT and surgery for PP significantly improves the OS, despite an increased risk of SPM with RT. Our study also shows a significant racial disparity in the long-term OS of PP.
Comprehensive assessment of the feasibility of adoptive cell therapy in colorectal carcinoma
Authors: B. Navarro Rodrigo, S. Viganò, P.O. Gannon, P. Baumgartner, C. Maisonneuve, C. Sempoux, M.-O. Sauvain, D. Hahnloser, M. Hubner, N. Demartines, L. Kandalaft, M. Montemurro, A. Harari, G. Coukos
Journal: Annals of Oncology (2016)
OS1.2 Effects of the IDH1R132H mutation on redox-status and metabolism are cell type dependent but independent from D-2-hydroxyglutarate accumulation
Authors: B. Klink, J. Biedermann, M. Lehmann, M. Peitzsch, M. Meinhardt, L. Kunz-Schughart, A. Temme, C. Herold-Mende, S. P. Niclou, E. Schröck
Journal: Neuro-Oncology (2016)

the control arm; whereas 19% of patients in the combination arm continued bevacizumab at progression.CONCLUSIONS: Adding bevacizumab to lomustine treatment in patients with progressive glioblastoma despite prolonged PFS does not confer a survival advantage compared to lomustine treatment.Future molecular and neuroimaging research should identify those patients deriving benefit from that treatment.
ENDOLA : A GINECO-GINEGEPS French NCI sponsored phase I/II trial to assess the safety and efficacy of metronomic cyclophosphamide, metformin and OLAparib in recurrent advanced/metastatic ENDometrial cancer patients
Authors: B. You, A. Dugue, A. Leary, M. Rodrigues, P. Follana, D. Maucort-Boulch, S. Verane, M. Tod, G. Freyer
Journal: Annals of Oncology (2016)
Observational study for MTHFR, TSER and DPYD gene mutation-associated toxicity and response in patients with rectal cancer receiving pre-operative chemo-radiotherapy
Authors: S. Mancarella, D. De Giorgi, O. Poti ', M.M. Galante, M.P. Trisolini, G. De Maria, M.L. Schirinzi, A. Rizzo
Journal: Annals of Oncology (2016)
Prediction of total clearance by UGT1A and ABC genes polymorphisms can predict tumor response and proteinuria in axitinib treatment for advanced renal cell carcinoma
Authors: H. Matsuyama, Y. Yamamoto, Y. Kawai, Y. Fujita, Y. Hamamoto, K. Matsuyama, T. Otori, J. Haginaka
Journal: Annals of Oncology (2016)